Coave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for suprachoroidal delivery
Coave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for suprachoroidal delivery CoTx-101 represents a potential breakthrough for patients with retinal vascular diseases, offering the efficacy and safety of biologics with the unique durability of gene therapy Suprachoroidal delivery enables an in-office procedure targeting the back of the eye […]